A+C in Metastatic Lung Adenocarcinoma Cancer
NCT02946359
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Lung Adenocarcinoma Metastatic
Interventions
DRUG:
Crizotinib, bevacizumab
Sponsor
Chinese PLA General Hospital